Latest News
August 03, 2021
Not intended for U.S. and UK Media
Bayer’s investigational P2X3 antagonist meets primary efficacy endpoint and shows favorable safety and tolerability profile
July 26, 2021
BlueRock Therapeutics Announces New Board Chair, New President and CEO
July 26, 2021
Bayer announces Prof. Dr. Dominik Ruettinger as new Head of Research and Early Development for Oncology
July 21, 2021
Not intended for U.S. and UK Media
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
July 19, 2021
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson’s Disease
Global Health Policy Blog
Current Topics
All